Skip to main content
Top
Published in: Clinical Rheumatology 2/2005

01-04-2005 | Case Report

Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C

Authors: Timothy B. Niewold, William I. Swedler

Published in: Clinical Rheumatology | Issue 2/2005

Login to get access

Abstract

We present the case of a 53-year-old woman who developed systemic lupus erythematosus (SLE) after being treated with interferon-alpha (IFN-α) for cryoglobulinemic vasculitis associated with hepatitis C virus (HCV) infection. Her cryoglobulinemic vasculitis resolved rapidly with IFN-α treatment. However, after 10 months of IFN-α therapy, she developed a photosensitive malar rash, oral ulcers, arthralgias, lymphopenia, and anti-SSA autoantibodies. She was diagnosed with SLE induced by IFN-α therapy. IFN-α was discontinued, she was treated with a short course of prednisone and hydroxychloroquine, and she improved rapidly. This is the first report of IFN-α-induced SLE complicating treatment of cryoglobulinemic vasculitis associated with HCV infection. The development of SLE during therapy with IFN-α could be due to direct immunomodulation by IFN-α, and review of experimental data and prior case reports suggests a pathogenic role for IFN-α in SLE.
Literature
1.
go back to reference Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431–1442CrossRefPubMed Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431–1442CrossRefPubMed
2.
go back to reference Krause I, Valesini G, Scrivo R, Shoenfeld Y (2003) Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115:390–397CrossRefPubMed Krause I, Valesini G, Scrivo R, Shoenfeld Y (2003) Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115:390–397CrossRefPubMed
3.
go back to reference Ronnblom LE, Alm GV, Oberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207–210PubMed Ronnblom LE, Alm GV, Oberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207–210PubMed
4.
go back to reference Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536–1537PubMed Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536–1537PubMed
5.
go back to reference Mehta ND, Hooberman AL, Vokes EE, Neeley S, Cotler S (1992) 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy. Am J Hematol 41:141PubMed Mehta ND, Hooberman AL, Vokes EE, Neeley S, Cotler S (1992) 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy. Am J Hematol 41:141PubMed
6.
go back to reference Tolymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C (1992) Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 120:429–432PubMed Tolymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C (1992) Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 120:429–432PubMed
7.
go back to reference Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65:70–74CrossRefPubMed Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65:70–74CrossRefPubMed
8.
go back to reference Hory B, Blanc D, Saint-Hiller Y (1992) Systemic lupus erythematosus-like syndrome induced by alpha-interferon therapy. Eur J Med 1:379PubMed Hory B, Blanc D, Saint-Hiller Y (1992) Systemic lupus erythematosus-like syndrome induced by alpha-interferon therapy. Eur J Med 1:379PubMed
9.
go back to reference Flores A, Olive A, Feliu E, Tena X (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33:787 Flores A, Olive A, Feliu E, Tena X (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33:787
10.
go back to reference Yoshida A, Takeda A, Koyama K, Morozumi K, Oikawa T (1994) Systemic lupus erythematosus with nephropathy after interferon-α 2A therapy. Clin Rheumatol 13:382 Yoshida A, Takeda A, Koyama K, Morozumi K, Oikawa T (1994) Systemic lupus erythematosus with nephropathy after interferon-α 2A therapy. Clin Rheumatol 13:382
11.
go back to reference Morris LF, Lemak NA, Arnett FC, Jordon RE, Duvic M (1996) Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 89:810–814PubMed Morris LF, Lemak NA, Arnett FC, Jordon RE, Duvic M (1996) Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 89:810–814PubMed
12.
go back to reference Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K (2000) Systemic lupus erythematosus after α-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 95:310PubMed Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K (2000) Systemic lupus erythematosus after α-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 95:310PubMed
13.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
14.
go back to reference Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237–2242PubMed Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237–2242PubMed
15.
go back to reference Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T (1987) Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 70:562–569PubMed Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T (1987) Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 70:562–569PubMed
16.
go back to reference Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540–1543CrossRefPubMed Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540–1543CrossRefPubMed
Metadata
Title
Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C
Authors
Timothy B. Niewold
William I. Swedler
Publication date
01-04-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1024-2

Other articles of this Issue 2/2005

Clinical Rheumatology 2/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.